Rockwell Medical, a healthcare company that develops, manufactures, commercialises, and distributes a portfolio of haemodialysis products to dialysis providers worldwide, today announced that Jesse Neri was promoted to chief financial officer (CFO).
“Over the past year, Jesse has been instrumental in strengthening Rockwell’s financial infrastructure, reshaping our financial strategy, and developing a stronger public company financial organisation and presence within the investor community,” said Mark Strobeck, president and chief executive officer (CEO) at Rockwell Medical. “His promotion to CFO is a testament to his invaluable contributions and leadership within Rockwell and underscores our focus on driving long-term strategic growth and exercising strong fiscal discipline.”
With nearly 25 years’ experience leading finance functions at both public and private companies, Neri joined Rockwell Medical in October 2023 as senior vice president (SVP) of finance to oversee all aspects of the company’s finance organisation. Prior to joining Rockwell Medical, Neri was the executive director of finance at Hemavant Sciences and Aruvant Sciences, clinical-stage biopharmaceutical companies that are members of the Roivant portfolio that develop therapeutics to improve the lives of patients with blood disorders and haematological malignancies. Previously, Neri served as SVP of finance at Zyla Life Sciences, a public pharmaceutical company with annual revenue of US$80 million. As a member of the senior management team, Neri was responsible for all aspects of its finance organisation including US Securities and Exchange Commission (SEC) reporting, audit, controllership, and strategic planning. While at Zyla, he played a pivotal role in multiple product acquisitions, financings, commercial product launches and regulatory approvals, along with Zyla’s acquisition by Assertio Therapeutics in May 2020. Prior to Zyla, Neri served as Vice President of financial planning and analysis at Symphony Health Solutions, a private equity-backed market research company with revenue of over US$200 million.
